74 Gartside Street
10 articles with 4D Pharma
4D pharma plc, a pharmaceutical company focusing on the development of Live Biotherapeutics, announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn's disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego.
4D pharma plc announces its participation in the Neuro4D conference, Frankfurt, Germany, 13-14 May, 2019.
4D pharma plc announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518.
4D Pharma plc announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.
4D pharma plc today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.
4D pharma plc and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.
Dr. Alex Stevenson, has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics.
4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours
4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products